Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Endo International plc
  6. Financials
    ENDP   IE00BJ3V9050

ENDO INTERNATIONAL PLC

(ENDP)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Valuation
Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization1 1 6381 0641 6531 062--
Entreprise Value (EV)1 8 7478 0038 7557 8047 3856 980
P/E ratio -1,70x-2,51x9,09x4,06x3,67x-
Yield ------
Capitalization / Revenue 0,56x0,36x0,57x0,39x0,39x0,40x
EV / Revenue 2,97x2,75x3,02x2,86x2,72x2,60x
EV / EBITDA 6,54x6,40x6,44x6,19x5,80x5,55x
Price to Book -3,29x-1,22x-2,54x-1,60x-8,53x-
Nbr of stocks (in thousands) 224 345226 776230 292233 305--
Reference price (USD) 7,304,697,184,554,554,55
Announcement Date 02/28/201902/26/202002/25/2021---
1 USD in Million
Estimates
Income Statement Evolution (Annual data)
Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales1 2 9472 9142 9032 7282 7132 682
EBITDA1 1 3381 2501 3601 2611 2731 258
Operating profit (EBIT)1 1 2371 1811 2911 1451 1491 140
Operating Margin 42,0%40,5%44,5%42,0%42,3%42,5%
Pre-Tax Profit (EBT) -939-345----
Net income1 -1 031-42318412221683,3
Net margin -35,0%-14,5%6,34%4,46%7,95%3,11%
EPS2 -4,29-1,870,791,121,24-
Dividend per Share2 ------
Announcement Date 02/28/201902/26/202002/25/2021---
1 USD in Million
2 USD
Income Statement Evolution (Quarterly data)
Fiscal Period: December 2020 Q3 2020 Q4 2021 Q1 2021 Q2 2021 Q3 2021 Q4
Net sales1 635760718666657686
EBITDA1 286344365322298316
Operating profit (EBIT)1 263326338274264278
Operating Margin 41,5%42,9%47,1%41,1%40,2%40,5%
Pre-Tax Profit (EBT) -64,8-47,8---
Net income1 -75,911941,530,224,525,4
Net margin -12,0%15,7%5,78%4,53%3,73%3,70%
EPS -0,330,510,17---
Dividend per Share ------
Announcement Date 11/05/202002/25/202105/06/2021---
1 USD in Million
Previous periodNext period
Balance Sheet Analysis
Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt1 7 1096 9407 1016 7436 3245 919
Net Cash position1 ------
Leverage (Debt / EBITDA) 5,31x5,55x5,22x5,35x4,97x4,71x
Free Cash Flow1 18034,2327791803702
ROE (Net Profit / Equities) ----481%67,3%
Shareholders' equity1 ----44,8124
ROA (Net Profit / Asset) 6,09%5,65%7,19%5,74%5,14%-
Assets1 -16 929-7 4802 5592 1174 195-
Book Value Per Share2 -2,22-3,83-2,83-2,84-0,53-
Cash Flow per Share 1,19-----
Capex1 86,963,970,099,7100100
Capex / Sales 2,95%2,19%2,41%3,65%3,69%3,73%
Announcement Date 02/28/201902/26/202002/25/2021---
1 USD in Million
2 USD
Analysis
Drugmakers, pharmacies next targets for U.S. opioid settlements
Key data
Capitalization (USD) 1 061 539 233
Net sales (USD) 2 903 074 000
Number of employees 3 397
Sales / Employee (USD) 854 599
Free-Float 98,5%
Free-Float capitalization (USD) 1 045 197 580
Avg. Exchange 20 sessions (USD) 44 743 410
Average Daily Capital Traded 4,21%
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA